Yi Sang sold $347K of ZBH

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

Zimmer Biomet (NYSE:ZBH) reported Q2 adjusted EPS of $2.07, above the $2.01 consensus, and revenue of $2.18B, up 4.8% year over year and above the $2.14B estimate. The company raised FY2026 guidance to $8.47-$8.59 adjusted EPS and 3.9%-4.9% reported sales growth, and expects up to $1B in share repurchases.

Zimmer Biomet reported Q2 revenue of about $2.18bn, up 4.8% YoY. Knees led at $828.9m, followed by S.E.T. at $586m and hips at $562.7m. The company raised its 2026 revenue growth outlook to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59 per diluted share. Shares rose over 5% to about $101 at the open.

Zimmer Biomet (ZBH) reported Q2 net earnings of $198.3 million, or $1.03 per share, versus $152.8 million, or $0.77 per share, a year earlier. Net sales rose to $2,177.0 million from $2,077.3 million. For FY2026, it raised reported revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares were up pre-market to $100.15.

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.

Zimmer Biomet (ZBH) reported Q2 2026 net sales of $2.177B (+4.8%) and GAAP diluted EPS of $1.03 (+33.8%), with technology sales up 53% in the U.S. Hip sales grew about 6% and knees were nearly flat. The company raised 2026 organic revenue growth to 2.25%–3.25% and adjusted EPS to $8.47–$8.59, and plans up to $1B buybacks.